Search Results - Drug addicts~

Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /

Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series

Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /

Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series

Changing paradigms in anticancer drug development inhibiting angiogenesis in colorectal cancer /

Table of Contents: “…Contents: Targeted therapy for cancer -- Angiogenesis is involved throughout tumour formation, growth and metastasis -- VEGF: molecular characteristics -- VEGF and other signals promote the angiogenic switch in tumours -- Tumour vasculature is abnormal -- VEGF produces immature tortuous vessels dependent on VEGF for survival -- Other features make VEGF an attractive target for anticancer therapy -- RhuMAb VEGF (bevacizumab/Avastin®) -- Significant reduction in microvasculature -- Anti-VEGF antibody improves drug delivery -- Avastin: an anti-VEGF agent for cancer therapy -- Use of Avastin with oxaliplatin-based therapy -- Addition of Avastin to oxaliplatin-based chemotherapy improved best confirmed response -- Study schema and organization.…”
Get full text
Series

Practicing harm reduction psychotherapy : an alternative approach to addictions / by Denning, Patt, 1950-

Practicing harm reduction psychotherapy : an alternative approach to addictions / by Denning, Patt, 1950-

Disorders of gastric function gastroparesis and functional dyspepsia, part 1 of 2 /

Table of Contents: “…Contents: Symptoms, definition and epidemiology of gastroparesis -- Gastroparesis consortium -- Diabetes and gastroparesis -- Causes of gastroparesis -- Molecular pathophysiology -- Factors that slow gastric emptying -- Range of gastric dysmotility -- Evaluation of gastroparesis -- Gastric emptying scans and tests -- Medications that slow gastric emptying -- Dietary recommendations -- Prokinetic therapies such as Metoclopramide and Erythromycin -- Antiemetic therapies -- Abdominal pain in gastroparesis -- NORIG -- Additional treatments such as Botox and gastric stimulation -- Future drugs -- Non-drug treatments.…”
Get full text
Series

Disorders of gastric function gastroparesis and functional dyspepsia, part 1 of 2 /

Table of Contents: “…Contents: Symptoms, definition and epidemiology of gastroparesis -- Gastroparesis consortium -- Diabetes and gastroparesis -- Causes of gastroparesis -- Molecular pathophysiology -- Factors that slow gastric emptying -- Range of gastric dysmotility -- Evaluation of gastroparesis -- Gastric emptying scans and tests -- Medications that slow gastric emptying -- Dietary recommendations -- Prokinetic therapies such as Metoclopramide and Erythromycin -- Antiemetic therapies -- Abdominal pain in gastroparesis -- NORIG -- Additional treatments such as Botox and gastric stimulation -- Future drugs -- Non-drug treatments.…”
Get full text
Series

Rheumatoid arthritis part 2 of 2 /

Get full text

Rheumatoid arthritis part 2 of 2 /

Get full text